Adopting Novel Technologies To Improve Monoclonal Antibody Processes
Source: Avantor
New bispecific antibodies show better cancer-fighting promise as compared to traditional monoclonal antibodies, but they can create process difficulties. Avantor’s Dr. Nandu Deokar talks about four new-edge production technologies that better remove impurities, reduce aggregation and improve stability; including viral inactivation that overcomes REACH concerns, newly designed chromatography ligand, additives in wash step and novel excipients in formulation buffer.
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Avantor
This website uses cookies to ensure you get the best experience on our website. Learn more